METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES
US-2024076619-A1 · Mar 7, 2024 · US
US9840693B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9840693-B2 |
| Application number | US-201715411125-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 20, 2017 |
| Priority date | Jan 23, 2014 |
| Publication date | Dec 12, 2017 |
| Grant date | Dec 12, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.
Opening claim text (preview).
The invention claimed is: 1. A method of growing cells comprising placing an isolated cell on or in a hydrogel under conditions such that the cell replicates, wherein hydrogel comprises a recombinant polypeptide in combination with a hydrogel polypeptide, wherein the recombinant polypeptide comprises a cell signaling sequence, wherein the cells signal sequence comprises SEQ ID NO: 1, fused to a hydrogel polypeptide sequence, wherein the hydrogel polypeptide and the recombinant polypeptide are in a ratio of between 1:5 to 1:15 by weight, and wherein the hydrogel polypeptide and the recombinant peptide are 1.5% to 2.5% by weight to volume of the hydrogel. 2. The method of claim 1 , wherein the isolated cell is a stem cell, progenitor cell, cardiac stem cell, cardiac progenitor cell, bone marrow derived cell, or mesenchymal stem cell. 3. The method of claim 2 , wherein the cardiac progenitor cell is isolated by the process of selecting cells for stem cell surface markers, progenitor cell surface markers, or cardiac cell surface markers. 4. The method of claim 1 , wherein the hydrogel comprises a saccharide at a concentration of between 100 nm to 500 mM. 5. The method of claim 1 , wherein the hydrogel comprises a buffer creating a pH of between 7.0 to 7.7. 6. The method of claim 1 , wherein the hydrogel further comprising a cardiac progenitor cell.
Molecules with a "CD"-designation not provided for elsewhere · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44) · CPC title
Proteins · CPC title
General culture methods using substrates (for specific animal cell type C12N5/06) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.